Question 1

What was the cost-per-QALY for semaglutide 2.4 mg before and after the STEP-1 Extension data were incorporated?

Accepted Answer

Pre-extension models, including ICER's 2022 analysis, estimated approximately $24,000 per QALY at net price with a partial-durability assumption. Post-extension recalibrations that model near-complete weight regain at one year after stopping raise that estimate to roughly $45,000 to $55,000 at net price. At list price, neither scenario clears the standard $100,000 threshold comfortably, and the extension data meaningfully narrow the margin.

Question 2

Does the SELECT cardiovascular outcomes trial change the economic calculation?

Accepted Answer

Yes, substantially for the right patient profile. SELECT showed a 20% reduction in MACE in patients with overweight or obesity and established CVD. Because that cardiovascular benefit may be partially independent of weight loss, the cost-effectiveness calculation for CVD-risk patients is more favorable than for patients seeking weight reduction alone. Models that incorporate SELECT for the CVD subpopulation recover QALY value lost from the weight-regain assumption, but this applies to a minority of current prescriptions.

Question 3

Why does the list price vs. net price distinction matter so much for coverage decisions?

Accepted Answer

Payers make formulary inclusion decisions based on net price after rebates. The difference between a $19,000 list price and a $9,800 net price represents the entire margin between cost-effective and cost-ineffective at common willingness-to-pay thresholds. Patients without coverage see list price, or list price minus a manufacturer coupon, and the gap to affordability for lifelong therapy is substantial at median US household income levels.

Question 4

Is semaglutide covered by Medicare Part D for obesity?

Accepted Answer

As of 2024, Medicare Part D coverage for Wegovy remains restricted by the statutory exclusion of drugs used primarily for weight loss, which Congress has not yet repealed. Patients with a covered comorbidity such as T2D may access lower-dose semaglutide (Ozempic) under that indication, but the 2.4 mg obesity dose is generally not covered for Medicare beneficiaries without CVD qualifying under any emerging CMS policy.

Question 5

What does the STEP-1 Extension mean for patients who need to stop due to cost or side effects?

Accepted Answer

The extension data predict that most of the weight lost (roughly two-thirds) will return within 12 months of stopping. For patients who tolerated the drug and achieved metabolic improvements, this means cardiometabolic benefits are also likely to partially reverse. Clinicians should counsel patients on this trajectory before initiation so the decision to start is made with full awareness of the chronic-therapy commitment required.

Question 6

Do all patients regain weight at the same rate after stopping?

Accepted Answer

No. The STEP-1 Extension reports population means, and individual trajectories vary. Patients with lower baseline weight or less metabolic dysfunction at enrollment appeared to have somewhat less dramatic regain in post-hoc analyses, but the sample size was too small (N=327) to draw firm subgroup conclusions. Longer-duration real-world discontinuation data are needed.

Question 7

How do payer step-therapy requirements affect the cost-effectiveness calculation in practice?

Accepted Answer

Step-therapy requirements mandate trials of lower-cost alternatives (typically phentermine-topiramate or orlistat) before semaglutide is authorized. If patients spend 6 to 12 months on less-effective medications before accessing semaglutide, the lifetime-horizon QALY benefit from semaglutide may be modestly reduced by delayed initiation, while costs accumulate from the step-therapy agents. From a system perspective, step therapy may not reduce total cost if it delays metabolic benefits in high-risk patients.

Question 8

What is the Treat and Reduce Obesity Act and would it change the economics?

Accepted Answer

The Treat and Reduce Obesity Act is pending federal legislation that would direct CMS to cover FDA-approved anti-obesity pharmacotherapies under Medicare Part D. Passage would make semaglutide accessible to the large Medicare-eligible population that overlaps most closely with the SELECT trial population. Budget-impact analyses suggest the near-term cost to Medicare would be substantial, but longer-horizon models incorporating MACE reduction and reduced hospitalizations may show net savings over a 10-year window, particularly if negotiated pricing under the Inflation Reduction Act is applied.

Question 9

Are there any cost-effectiveness analyses that specifically used the STEP-1 Extension weight-regain trajectory as the primary durability input?

Accepted Answer

Several post-2022 economic models updated their durability assumptions following the extension publication, including sensitivity analyses in the ICER report addenda and independent analyses published in journals such as Pharmacoeconomics and Value in Health. None were pre-specified within the extension trial itself, because the extension was a clinical follow-on study, not an economic analysis. The SELECT cardiovascular outcomes data have since introduced additional complexity that ongoing modeling exercises are still integrating.

Question 10

What should a patient use to decide whether the cost is worth it personally?

Accepted Answer

The individual calculation depends on baseline cardiovascular risk, likelihood of continuous coverage, out-of-pocket cost after insurance, and personal quality-of-life value assigned to weight change. Patients with established CVD, T2D, or high 10-year ASCVD risk derive the largest measurable clinical benefit and have the most favorable individual value ratio, especially if coverage is stable. Patients with BMI just above threshold, no comorbidities, and uncertain coverage face the least favorable calculation because the benefit is smaller and the chronic-use commitment is longer relative to gain.

STEP-1 Extension Cost, Cost-Effectiveness, and Health-Economic Implications

At a glance

Why the Extension Data Rewrites the Cost Model

What Published Cost-Effectiveness Models Actually Found

Pre-Extension Models (2021 to Early 2022)

Post-Extension Recalibrations

List Price vs. Net Price: The Number That Actually Drives Coverage Decisions

Modeling the Individual Patient's Relative-Value Calculation

Payer Coverage Implications: The Chronic-Disease Framing Problem

Key Limitations the Authors Acknowledged

Frequently asked questions

References